# Enavate Sciences

Enavate Sciences is an Asset Manager based in New York, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** Menlo Park, CA, United States
- **Founded:** 2022
- **Assets under management:** $300M - $500M (Altss estimate)
- **Website:** enavatesciences.com
- **LinkedIn:** https://www.linkedin.com/company/enavate-sciences

## Regulatory record

- **Reports private funds:** No

## About

Enavate Sciences invests in and supports life sciences companies, focusing on pre-clinical and clinical stage firms in various therapeutic areas. The company prioritizes companies with growth potential and unmet medical needs. It is headquartered in California, United States.

## Sectors

- Digital Health
- Healthcare Services
- AI/ML

## Offices

- New York, NY
- Greenwich, CT

## People

- James Healy — Managing Partner

## Questions

### How is Enavate Sciences structured relative to Patient Square Capital?

Patient Square Capital established Enavate Sciences as a separate operating entity in 2022 with approximately $300 million in committed capital. Patient Square remains the sole capital provider, but Enavate operates independently with its own management team and investment committee. The structure allows Enavate to focus exclusively on acquiring and building therapeutic programs, while Patient Square continues its broader healthcare private equity strategy.

### Does Enavate Sciences make fund commitments or only direct investments?

Enavate Sciences does not invest in third-party venture funds. The firm makes direct equity investments, taking controlling or significant minority positions in therapeutic programs and platform companies. Enavate also structures in-licensing deals and university partnerships, such as its disclosed collaboration with Yale University on a neuroinflammation program.

### What investment stages does Enavate Sciences target?

Enavate targets preclinical and early clinical-stage programs that have scientific validation but require operational and strategic resources to reach proof of concept. The firm builds companies around assets — sometimes licensing a program from an academic lab and assembling the startup team internally — rather than writing checks into existing management-led rounds. It will also acquire de-prioritized clinical assets from larger pharmaceutical companies.

### Who runs investment decisions at Enavate Sciences?

James Healy, a managing partner and former managing director at Patient Square Capital, leads Enavate's investment and operational decisions. Prior to Patient Square, Healy held senior investment roles at Sofinnova Investments and was a partner at Redmile Group, where he focused on public and private biotech. His background spans venture creation and asset-centric drug development.

### Which therapeutic modalities does Enavate Sciences pursue?

Enavate is modality-agnostic and will pursue small molecules, biologics, cell therapies, and gene therapies where the underlying biology is compelling. Publicly disclosed portfolio programs span gene therapy for neuro-oncology (Disco Therapeutics) and small-molecule approaches in neuroinflammation. The firm has indicated openness to nucleic-acid therapeutics and radiopharmaceuticals as well.

## Related profiles

- [Ltd.](https://altss.com/profile/ltd)
- [Southwire](https://altss.com/profile/southwire-company)

---

Last updated: 2026-07-09T00:27:34.523Z

Canonical page: https://altss.com/profile/enavate-sciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology